18 results
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
Le présent document remplace la note de synthèse de 2016 de l’OMS relative au premier vaccin homologué contre la dengue, le CYD-TDV. En novembre 2017, les résultats d’une analyse...
Le Programme pour la vaccination à l’horizon2030 établit une vision et une stratégie mondiales ambitieuses pour les vaccins et la vaccination durant la décennie 20212030. Il s’appuie sur les...
Dengue vaccines are now in clinical development phases. Dengue vaccine trials represent a major given the specific epidemiology and clinical manifestations of the disease. Moreover, there are...
Following publication of results from two phase-3 clinical trials in 10 countries or territories, endemic countries began licensing the first dengue vaccine in 2015. Using a published mathematical...
In 2013, the Council for International Organizations of Medical Sciences (CIOMS) created a Working Group on Vaccine Safety (WG) to address unmet needs in the area of vaccine pharmacovigilance....
Vaccines are a cornerstone of modern health systems. A few shots can protect a child for life against diseases such as diphtheria and cholera. While many of us take vaccines for granted, every year,...
This is the first WHO position paper on a dengue vaccine. It focuses primarily on the available evidence concerning the only dengue vaccine to have been registered by National Regulatory Authorities...
Background
Dengue is the most common arbovirus infection globally, but its burden is poorly quantified. We estimated dengue mortality, incidence, and burden for the Global Burden of Disease Study...
A dengue vaccine is expected to be available within a few years. Once vaccine is available, policy-makers will need to develop suitable policies to allocate the vaccine. Mathematical models of dengue...
Dengue virus is the most serious mosquito-borne viral threat to public health and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent DENVax vaccine contains a...
The need for a dengue vaccine is more pressing than ever. Dengue—a mosquito-borne viral infection caused by any of the four dengue virus serotypes—is regarded as the most important arboviral...
Because a dengue vaccine should be tetravalent in nature and provide protection against all four dengue serotypes, regulatory agencies need to address additional issues associated with multi-valent...
In May 2009, a group of international experts on dengue, vaccine quality and clinical evaluation met together (i) to review disease, vaccine pipeline, quality issues in manufacturing, issues of...
A recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has been assessed in two phase 3 randomized efficacy trials involving more than 31,000 children between the ages of 2 and 14...
Why was there a loss of vaccine confidence in the Philippines? What were the consequences of this confidence crisis? How was this issue addressed?